[go: up one dir, main page]

MX9802764A - Promotor homologo fuerte procedente de un hamster. - Google Patents

Promotor homologo fuerte procedente de un hamster.

Info

Publication number
MX9802764A
MX9802764A MX9802764A MX9802764A MX9802764A MX 9802764 A MX9802764 A MX 9802764A MX 9802764 A MX9802764 A MX 9802764A MX 9802764 A MX9802764 A MX 9802764A MX 9802764 A MX9802764 A MX 9802764A
Authority
MX
Mexico
Prior art keywords
hamsters
intensive
promoter obtained
homologous promoter
promoter
Prior art date
Application number
MX9802764A
Other languages
English (en)
Inventor
Barbara Enenkel
Frank Gannon
Klaus Bergemann
Wolfgang Noe
Original Assignee
Thomae Gmbh Dr K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomae Gmbh Dr K filed Critical Thomae Gmbh Dr K
Publication of MX9802764A publication Critical patent/MX9802764A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

El invento concierne a un promotor homologo fuerte procedente de un hámster. Especialmente, se trata en tal caso del promotor del gen, que codifica la proteína de fusion de ubiquitina-S27a. El promotor se puede utilizar para procedimientos destinados a la preparacion de productos génicos heterologos en células cultivadas, especialmente en células de CHO.
MX9802764A 1995-10-24 1998-04-07 Promotor homologo fuerte procedente de un hamster. MX9802764A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19539493A DE19539493A1 (de) 1995-10-24 1995-10-24 Starker homologer Promotor aus Hamster

Publications (1)

Publication Number Publication Date
MX9802764A true MX9802764A (es) 1998-11-30

Family

ID=7775593

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9802764A MX9802764A (es) 1995-10-24 1998-04-07 Promotor homologo fuerte procedente de un hamster.

Country Status (11)

Country Link
US (1) US6063598A (es)
EP (2) EP1803815A3 (es)
JP (2) JP3966903B2 (es)
AT (1) ATE355370T1 (es)
CA (1) CA2234071C (es)
DE (2) DE19539493A1 (es)
DK (1) DK0857211T3 (es)
ES (1) ES2281905T3 (es)
MX (1) MX9802764A (es)
PT (1) PT857211E (es)
WO (1) WO1997015664A1 (es)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998032869A1 (en) * 1997-01-29 1998-07-30 Neurosearch A/S Expression vectors and methods for in vivo expression of therapeutic polypeptides
AU2001290984A1 (en) * 2000-09-18 2002-04-02 Genzyme Corporation Expression vectors containing hybrid ubiquitin promoters
EP1624067A3 (en) * 2000-09-18 2006-03-15 Genzyme Corporation Expression vectors containing hybrid ubiquitin promoters
DE60236331D1 (de) * 2001-07-04 2010-06-17 Chromagenics Bv DNS-Sequenzen mit Anti-Repressor-Aktivität
US7384744B2 (en) 2002-11-29 2008-06-10 Boehringer Ingelheim Pharma Gmbh & Co., Kg Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
US7344886B2 (en) * 2002-11-29 2008-03-18 Boehringer Ingelheim Pharma Gmbh & Co., Kg Neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product
DE10256083A1 (de) 2002-11-29 2004-08-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Expressionsvektor, Verfahren zur Herstellung von heterologen Genprodukten und Selektionsverfahren für hochproduzierende rekombinante Zellen
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
US8669109B2 (en) 2003-08-19 2014-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methods of producing proteins in Chinese hamster ovary (CHO) cells
US20050101017A1 (en) * 2003-11-10 2005-05-12 Wojtek Auerbach Method of improving gene targeting using a ubiquitin promoter
GB0509965D0 (en) * 2005-05-17 2005-06-22 Ml Lab Plc Improved expression elements
UA92913C2 (ru) * 2005-06-20 2010-12-27 Кадила Хелткере Лимитед Экспрессионный вектор и способы продуцирования высоких уровней белков
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
US20080124760A1 (en) * 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
KR101600733B1 (ko) 2011-10-28 2016-03-09 프로테나 바이오사이언시즈 리미티드 알파-시누클레인을 인식하는 인간화된 항체
JP6342333B2 (ja) 2012-01-27 2018-06-13 プロセナ バイオサイエンシーズ リミテッド α−シヌクレインを認識するヒト化抗体
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
WO2014102101A1 (en) 2012-12-31 2014-07-03 Boehringer Ingelheim International Gmbh Novel intron sequences
EP2938726B1 (en) 2012-12-31 2017-09-27 Boehringer Ingelheim International GmbH Heterologous intron within a signal peptide
CU24446B1 (es) 2013-03-13 2019-10-04 Prothena Biosciences Ltd Un anticuerpo monoclonal humanizado que se une a tau
WO2014182972A2 (en) 2013-05-10 2014-11-13 The Regents Of The University Of California Diagnostic and monitoring system for huntington's disease
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
WO2015004632A1 (en) 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize iapp
WO2015004633A1 (en) 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize islet-amyloid polypeptide (iapp)
US11191832B2 (en) 2013-11-19 2021-12-07 Prothena Biosciences Limited Monitoring immunotherapy of Lewy body disease from constipation symptoms
DK3089760T3 (da) 2013-12-31 2020-03-16 Proteonic Biotechnology Ip B V Konstrukt og sekvens til forbedret genekspression
TW201623331A (zh) 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
US10059761B2 (en) 2014-03-12 2018-08-28 Prothena Biosciences Limited Anti-Laminin4 antibodies specific for LG4-5
CA2938931A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg1-3
DK3116911T3 (da) 2014-03-12 2019-09-30 Prothena Biosciences Ltd Anti-mcam-antistoffer og tilhørende fremgangsmåder til anvendelse
CA2944402A1 (en) 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
PH12021552108A1 (en) 2014-12-10 2022-05-11 Opko Biologics Ltd Methods of producing long acting ctp-modified growth hormone polypeptides
TWI781507B (zh) 2015-01-28 2022-10-21 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI711631B (zh) 2015-01-28 2020-12-01 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI718122B (zh) 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
US10881102B2 (en) 2015-05-18 2021-01-05 Zymtronix, Llc Magnetically immobilized microbiocidal enzymes
CN108140848B (zh) 2015-07-15 2022-02-01 齐姆特罗尼克斯公司 自动化生物纳米催化剂生产
WO2017046776A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2017153955A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153953A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
PL3452507T3 (pl) 2016-05-02 2023-01-09 Prothena Biosciences Limited Immunoterapia tau
BR112018072389A2 (pt) 2016-05-02 2019-02-19 Prothena Biosciences Limited anticorpos que reconhecem tau
MY197413A (en) 2016-05-02 2023-06-16 Prothena Biosciences Ltd Antibodies recognizing tau
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2018007922A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
EP3478715A2 (en) 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin antibodies
JP7017013B2 (ja) 2016-07-02 2022-02-08 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
SG10202100189WA (en) 2016-07-11 2021-02-25 Opko Biologics Ltd Long-acting coagulation factor vii and methods of producing same
WO2018034877A1 (en) 2016-08-13 2018-02-22 Zymtronix, Llc Magnetically immobilized biocidal enzymes and biocidal chemicals
CA3049766A1 (en) 2017-01-13 2018-07-19 The Regents Of The University Of California Immunoengineered pluripotent cells
BR112019022906A2 (pt) 2017-05-02 2020-05-26 Prothena Biosciences Limited Anticorpos que reconhecem tau
CA3076313A1 (en) 2017-09-28 2019-04-04 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
MX2020003043A (es) 2017-10-06 2020-10-05 Prothena Biosciences Ltd Métodos para detectar transtiretina.
MX2020005433A (es) 2017-11-29 2020-08-27 Prothena Biosciences Ltd Formulacion liofilizada de un anticuerpo monoclonal contra la transtirretina.
US20210263001A1 (en) 2018-09-05 2021-08-26 Zymtronix Catalytic Systems, Inc. Immobilized enzymes and microsomes on magnetic scaffolds
WO2020097561A1 (en) 2018-11-08 2020-05-14 Prothena Biosciences Limited Antibodies recognizing tau
MY205760A (en) 2018-11-26 2024-11-12 Forty Seven Inc Humanized antibodies against c-kit
CU20210073A7 (es) 2019-03-03 2022-04-07 Prothena Biosciences Ltd Anticuerpos que se unen dentro de la región de unión a microtúbulos de tau definida por cdrs
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
MX2021013713A (es) 2019-05-10 2021-12-10 Univ California Celulas pluripotentes modificadas.
AU2020307550A1 (en) 2019-06-26 2022-02-03 The Regents Of The University Of California SIRPalpha-silenced natural killer (NK) cells
JP2022543112A (ja) 2019-08-01 2022-10-07 サナ バイオテクノロジー，インコーポレイテッド Ｄｕｘ４発現細胞およびそれらの使用
US20230025289A1 (en) 2019-08-23 2023-01-26 Sana Biotechnology, Inc. Cd24 expressing cells and uses thereof
WO2021146222A1 (en) 2020-01-13 2021-07-22 Sana Biotechnology, Inc. Modification of blood type antigens
EP4585223A3 (en) 2020-01-15 2025-07-30 The Regents of the University of California Transplanted cell protection via inhibition of polymorphonuclear cells
EP4090747A1 (en) 2020-01-17 2022-11-23 Sana Biotechnology, Inc. Safety switches for regulation of gene expression
KR20220158046A (ko) 2020-03-25 2022-11-29 사나 바이오테크놀로지, 인크. 신경계 장애 및 병태의 치료를 위한 면역저하성 신경 세포
IL299329A (en) 2020-06-24 2023-02-01 Prothena Biosciences Ltd Antibodies recognizing sortilin
MX2023001831A (es) 2020-08-13 2023-06-29 Sana Biotechnology Inc Métodos de tratamiento de pacientes sensibilizados con células hipoinmunogénicas y métodos y composiciones asociados.
MX2023006207A (es) 2020-12-31 2023-08-09 Sana Biotechnology Inc Métodos y composiciones para modular la actividad de linfocitos t con receptores de antígenos quiméricos (t-car).
US20240252642A1 (en) 2021-05-19 2024-08-01 Sana Biotechnology, Inc. Hypoimmunogenic rhd negative primary t cells
JP2024521619A (ja) 2021-05-27 2024-06-04 サナ バイオテクノロジー，インコーポレイテッド 操作されたｈｌａ－ｅまたはｈｌａ－ｇを含む低免疫原性細胞
US20240316198A1 (en) 2021-07-14 2024-09-26 Sana Biotechnology, Inc. Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
WO2023019227A1 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
JP2024534772A (ja) 2021-08-11 2024-09-26 サナ バイオテクノロジー，インコーポレイテッド 同種異系細胞療法用の遺伝子改変細胞
EP4384189A1 (en) 2021-08-11 2024-06-19 Sana Biotechnology, Inc. Genetically modified primary cells for allogeneic cell therapy
WO2023019225A2 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
AU2023220128A1 (en) 2022-02-17 2024-08-22 Sana Biotechnology, Inc. Engineered cd47 proteins and uses thereof
WO2023173123A1 (en) 2022-03-11 2023-09-14 Sana Biotechnology, Inc. Genetically modified cells and compositions and uses thereof
WO2023183313A1 (en) 2022-03-22 2023-09-28 Sana Biotechnology, Inc. Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
TW202440929A (zh) 2022-12-14 2024-10-16 加拿大商普羅維登斯治療控股公司 用於感染性疾病的組合物和方法
WO2024151541A1 (en) 2023-01-09 2024-07-18 Sana Biotechnology, Inc. Type-1 diabetes autoimmune mouse
WO2024229302A1 (en) 2023-05-03 2024-11-07 Sana Biotechnology, Inc. Methods of dosing and administration of engineered islet cells
WO2024243236A2 (en) 2023-05-22 2024-11-28 Sana Biotechnology, Inc. Methods of delivery of islet cells and related methods
WO2025043172A1 (en) 2023-08-23 2025-02-27 Sana Biotechnology, Inc. Modified cd47 proteins and their uses
TW202525338A (zh) 2023-09-15 2025-07-01 愛爾蘭商普羅希那生物科學有限公司 細胞穿透劑及其用途
WO2025059486A1 (en) 2023-09-15 2025-03-20 Prothena Biosciences Limited Anti-tdp-43 antibodies and uses thereof
TW202528337A (zh) 2023-09-15 2025-07-16 愛爾蘭商普羅希那平台科技有限公司 包括細胞穿透藥劑之方法、組合物、及套組
AR133829A1 (es) 2023-09-15 2025-11-05 Othair Prothena Ltd Agentes penetrantes de células y usos de los mismos
WO2025166633A2 (en) 2024-02-07 2025-08-14 Westlake Genetech. Ltd. Split gene editing systems and uses thereof

Also Published As

Publication number Publication date
EP0857211B1 (de) 2007-02-28
US6063598A (en) 2000-05-16
EP1803815A3 (de) 2007-08-29
JP3966903B2 (ja) 2007-08-29
DE59611420D1 (de) 2007-04-12
CA2234071A1 (en) 1997-05-01
WO1997015664A1 (de) 1997-05-01
JP2006320330A (ja) 2006-11-30
CA2234071C (en) 2003-01-21
EP1803815A2 (de) 2007-07-04
JPH11513572A (ja) 1999-11-24
PT857211E (pt) 2007-03-30
EP0857211A1 (de) 1998-08-12
DK0857211T3 (da) 2007-03-26
ATE355370T1 (de) 2006-03-15
ES2281905T3 (es) 2007-10-01
DE19539493A1 (de) 1997-04-30

Similar Documents

Publication Publication Date Title
MX9802764A (es) Promotor homologo fuerte procedente de un hamster.
DK0770139T3 (da) En svamp, hvor areA-genet er blevet modificeret, samt et areA-gen fra aspergillus oryzae
WO1994025612A3 (fr) Sequences de nucleotides pour le controle de l'expression de sequences d'adn dans un hote cellulaire
EP1020528A3 (en) Method for producing secreted proteins
PL345408A1 (en) Overexpression of phytase genes in yeast systems
PL341760A1 (en) Expression cloning in mildew fungi
ZA935915B (en) Modified fungal cells and method for producing recombinant products
AU4355697A (en) High level expression of proteins
WO1994018316A3 (en) Apolipoprotein b mrna editing protein compositions and methods
IL130190A0 (en) Methods and compositions for polypeptide engineering
HU9502608D0 (en) Process for production of protein
NZ310710A (en) Fermentative production of hydrophobic proteins such as ifn-<beta>
DE69930955D1 (de) Polypeptide mit lysophospholipaseaktivität und nukleinesäuren die sie kodieren
DE69434614D1 (de) Cdn apoptosis modulierende proteine, sie kodierende dns und verfahren zu ihrer verwendung
IL135983A0 (en) Adenovirus vectors and method for reducing homologous recombination phenomena
IL88151A (en) Interleukin-7 protein, dna sequences encoding it, its preparation and compositions containing it
AU3802595A (en) Tripeptidyl aminopeptidase
AU6724794A (en) GRB3-3 gene, its variants and their uses
AU2085195A (en) Gene coding for igg-fc-binding protein
TW200502388A (en) Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
AU5727099A (en) A 2,6-beta-d-fructan hydrolase enzyme and processes for using the enzyme
AU1720397A (en) Recombinant expression of s-layer proteins
EP1010761A4 (en) UNCOMFORTABLE
GB9726897D0 (en) Process
NZ334744A (en) Method for determining expression of aberrant forms of APC protein

Legal Events

Date Code Title Description
FG Grant or registration